Outcome | Measurement tool | Measurement occasions |
Primary outcome | ||
Pain severity | Pain Severity Score of the Brief Pain Inventory | Baseline, weeks 2, 4, 6 and 12 |
Secondary outcomes | ||
Physical functioning (generic) | Pain Interference Score of the Brief Pain Inventory. | Baseline, weeks 2, 4, 6 and 12 |
Physical functioning (condition-specific) | Roland-Morris Disability Questionnaire (24 items, for participants reporting low back pain only) and Neck Disability Questionnaire (for participants reporting neck pain only) | Baseline and 6 weeks |
Time to recovery (average daily pain of 0 or 1 of 10 for the past seven consecutive days) | Pain diary | Daily until recovery or up to 12 weeks |
Quality of life (physical) | SF-12 | Baseline, weeks 2, 4, 6 and 12 |
Quality of life (mental) | SF-12 | Baseline, weeks 2, 4, 6 and 12 |
Participants’ rating of global improvement | Global Perceived Effect scale | Baseline, weeks 2, 4, 6 and 12 |
Other outcomes | ||
Adverse events | Self-report and doctor report |
Self-report at weeks 2, 4, 6 and 12 Doctor report after each follow-up visit |
Work absenteeism | Self-report | Baseline, weeks 2, 4, 6 and 12 |
Use of treatment or health care services | Self-report | Baseline, weeks 2, 4, 6 and 12 |
Compliance to study medication | Self-reported adherence recorded in a medication diary compared against doctor prescription data, supported by returned medicine count |
Medicine diary is recorded daily over 6 weeks Doctor prescription data at each visit Returned medicine count at end of treatment period (≤6 weeks) |
Success of blinding | Participants are asked to estimate their allocation group as active opioid, inactive placebo or do not know | Week 6 |
Long-term outcomes | ||
Pain severity | Pain Severity Score of the Brief Pain Inventory | Weeks 26 and 52 |
Use of treatment or health care services | Self-report | Weeks 26 and 52 if still experiencing low back pain and/or neck pain (> 1/10) |
Risk of misuse | Current Opioid Misuse Measure | Weeks 12, 26 and 52 |